These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 33546682)

  • 1. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry.
    Gao J; Kalafatis D; Carlson L; Pesonen IHA; Li CX; Wheelock Å; Magnusson JM; Sköld CM
    Respir Res; 2021 Feb; 22(1):40. PubMed ID: 33546682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
    Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
    BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
    Jo HE; Glaspole I; Grainge C; Goh N; Hopkins PM; Moodley Y; Reynolds PN; Chapman S; Walters EH; Zappala C; Allan H; Keir GJ; Hayen A; Cooper WA; Mahar AM; Ellis S; Macansh S; Corte TJ
    Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28232409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry.
    Wuyts WA; Dahlqvist C; Slabbynck H; Schlesser M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; Bondue B
    Respir Res; 2019 Oct; 20(1):231. PubMed ID: 31651324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
    Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
    Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden.
    Kalafatis D; Gao J; Pesonen I; Carlson L; Sköld CM; Ferrara G
    BMC Pulm Med; 2019 Nov; 19(1):222. PubMed ID: 31771560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
    Snyder L; Neely ML; Hellkamp AS; O'Brien E; de Andrade J; Conoscenti CS; Leonard T; Bender S; Gulati M; Culver DA; Kaner RJ; Palmer S; Kim HJ;
    Respir Res; 2019 May; 20(1):105. PubMed ID: 31142314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Justet A; Laurent-Bellue A; Thabut G; Dieudonné A; Debray MP; Borie R; Aubier M; Lebtahi R; Crestani B
    Respir Res; 2017 Apr; 18(1):74. PubMed ID: 28449678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
    Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
    Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
    Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
    Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema.
    Schmidt SL; Nambiar AM; Tayob N; Sundaram B; Han MK; Gross BH; Kazerooni EA; Chughtai AR; Lagstein A; Myers JL; Murray S; Toews GB; Martinez FJ; Flaherty KR
    Eur Respir J; 2011 Jul; 38(1):176-83. PubMed ID: 21148225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry.
    Štefániková M; Doubková M; Ovesná P; Šterclová M; Lacina L; Žurková M; Plačková M; Bartoš V; Janíčková I; Bittenglová R; Anton J; Sýkorová Ľ; Lošťáková V; Musilová P; Šuldová H; Mokošová R; Didyk J; Šišáková L; Lisá P; Lněnička J; Dařičková H; Doležel D; Pšikalová J; Tyl R; Králová R; Vašáková MK
    BMC Pulm Med; 2023 May; 23(1):154. PubMed ID: 37138274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of six-minute walk test in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Kim MJ; Nathan SD; Kim HH; Kim HC
    Ther Adv Respir Dis; 2024; 18():17534666241275329. PubMed ID: 39175212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis.
    Goobie GC; Ford-Sahibzada CA; Fritzler MJ; Johannson KA; Fell CD
    Respir Med; 2019 Jul; 153():85-90. PubMed ID: 31176275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.
    Bi Y; Rekić D; Paterniti MO; Chen J; Marathe A; Chowdhury BA; Karimi-Shah BA; Wang Y
    J Pharmacokinet Pharmacodyn; 2021 Feb; 48(1):55-67. PubMed ID: 32949322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.